$NAMS News
Last published 1d ago
- 1d agoNAMSGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - NEWAMSTERDAM PHARMA CO NVEarnings Call TranscriptsThank you for joining Guggenheim's 3rd Healthcare Innovation Conference. My name is Moritz. I'm part of the therapeutics team, and it's my privilege today to host Jens Amaya, CFO of New Amsterdam Pharma, and Matt Philipp
- 5d agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 5d agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
- 1w agoNAMSNAMSWNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial ResultsGlobeNewswire– Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib worldwide – –
- 1w agoNAMSNAMSWNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in NovemberGlobeNewswireNAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 1mo agoNAMSMenarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)PR NewswireNewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, ...
- 1mo agoNAMSNAMSWNewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)GlobeNewswire- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile- - First global regulatory approval of obicetrapib
- 2mo agoNAMSWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - NEWAMSTERDAM PHARMA CO NVEarnings Call TranscriptsThanks, everyone, for being here. My name is Yanen Zhu, and I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to be joined by the management team of New Amsterdam Pharma. With me here, Michael
- 2mo agoNVSIONSAMGNLLY+1Cholesterol drug setback casts doubt over multibillion-dollar raceCNBCNovartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
- 2mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for
- 2mo agoNAMSNAMSWNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in SeptemberGlobeNewswireNAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for
- 2mo agoNAMSNAMSWNewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026GlobeNewswireNAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 3mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, The Netherlands and MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 3mo agoNAMSNewAmsterdam Pharma Investor Day 2026 - NEWAMSTERDAM PHARMA CO NVEarnings Call TranscriptsAll right. Good morning, everybody. Thank you for joining us today for our Annual Investor Day. I'm pleased to have Michael Davidson, our CEO, John Castellane, our Chief Scientific Officer, and BJ Jones, our chief commer
- 3mo agoNAMSNAMSWNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial ResultsGlobeNewswire– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from
- 3mo agoNAMSNAMSWNewAmsterdam Pharma to Host Investor Day on August 5, 2026GlobeNewswireNAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 3mo agoNAMSNewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)PR NewswireNewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, ...
- 3mo agoNAMSNAMSWNewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)GlobeNewswire- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe - - Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and
- 3mo agoMBXARQTNAMSGNLXAttovia Therapeutics Appoints John W. Smither to Board of DirectorsGlobeNewswireSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for
- 4mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 4mo agoNAMSNAMSWNewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026GlobeNewswireNAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 5mo agoNAMSNAMSWNewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific SessionsGlobeNewswireNAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 5mo agoNAMSNAMSWNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneGlobeNewswireNAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 6mo agoNAMS2026 GLOBAL HEALTHCARE CONFERENCE - NEWAMSTERDAM PHARMA CO NVEarnings Call TranscriptsWell, good afternoon. Thank you for joining us on our first day of the annual Bank of America Healthcare Conference in extremely toasty Las Vegas. Ending up our final talk of the day is I'm very pleased to have join us t
- 6mo agoNAMSNAMSWNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MayGlobeNewswireNAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 6mo agoNAMSNewAmsterdam PREVAIL update call - NEWAMSTERDAM PHARMA CO NVEarnings Call TranscriptsGood day, everyone. My name is June and I will be your conference operator today. At this time, we would like to welcome you to the new Amsterdam Prevail update call. All lines have been placed on mute to prevent any bac
- 6mo agoNAMSNEWAMSTERDAM PREVAIL UPDATE CALL - NEWAMSTERDAM PHARMA CO NVEarnings Call TranscriptsGood day, everyone. My name is June and I will be your conference operator today. At this time, we would like to welcome you to the new Amsterdam Prevail update call. All lines have been placed on mute to prevent any bac
- 6mo agoNAMSNAMSWNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsGlobeNewswire– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26
- 6mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 7mo agoNAMSNAMSWNewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireNAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 7mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 7mo agoNAMSNAMSWNewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific SessionGlobeNewswireNAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 8mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, the Netherlands and MIAMI, March 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 8mo agoNAMSNAMSWNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MarchGlobeNewswireNAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 8mo agoNAMSNAMSWNewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with
- 9mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 9mo agoNAMSNAMSWNewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech SummitGlobeNewswireNAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 10mo agoNAMSNAMSWNewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic PrioritiesGlobeNewswire-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- First patient
- 10mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, the Netherlands and MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 11mo agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 11mo agoNAMSNAMSWNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in DecemberGlobeNewswireNAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 1y agoNAMSNAMSWNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 1y agoNAMSNAMSWNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial ResultsGlobeNewswire– Marketing Authorization Applications for obicetrapib and FDC of obicetrapib plus ezetimibe accepted for review by European Medicines Agency – – BROOKLYN and BROADWAY pooled MACE analysis published in the Journal of
- 1y agoNAMSNAMSWNewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in NovemberGlobeNewswireNAARDEN, The Netherlands and MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 1y agoNAMSCaristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and InflammationPR NewswireCaristo Diagnostics, on a mission to transform the diagnosis and treatment of cardiovascular disease, announced its role as the worldwide imaging...
- 1y agoNAMSNAMSWNewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic ForumGlobeNewswireNAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 1y agoNAMSNewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoNAMSNAMSWNewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in SeptemberGlobeNewswireNAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 1y agoNAMSPiramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania SitePR NewswirePiramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE:...
- 1y agoNAMSPiramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania SitePR NewswirePiramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE:...